Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 1
2015 5
2016 4
2017 9
2018 33
2019 29
2020 20
2021 19
2022 10
2023 2
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Major Extremity Trauma Research Consortium (METRC); O'Toole RV, Stein DM, O'Hara NN, Frey KP, Taylor TJ, Scharfstein DO, Carlini AR, Sudini K, Degani Y, Slobogean GP, Haut ER, Obremskey W, Firoozabadi R, Bosse MJ, Goldhaber SZ, Marvel D, Castillo RC. Major Extremity Trauma Research Consortium (METRC), et al. N Engl J Med. 2023 Jan 19;388(3):203-213. doi: 10.1056/NEJMoa2205973. N Engl J Med. 2023. PMID: 36652352 Clinical Trial.
Death occurred in 47 patients (0.78%) in the aspirin group and in 45 patients (0.73%) in the low-molecular-weight-heparin group (difference, 0.05 percentage points; 96.2% confidence interval, -0.27 to 0.38; P<0.001 for a noninferiority margin of 0.75 percentage points). …
Death occurred in 47 patients (0.78%) in the aspirin group and in 45 patients (0.73%) in the low-molecular-weight-heparin group (difference, …
PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients.
O'Toole RV, Stein DM, Frey KP, O'Hara NN, Scharfstein DO, Slobogean GP, Taylor TJ, Haac BE, Carlini AR, Manson TT, Sudini K, Mullins CD, Wegener ST, Firoozabadi R, Haut ER, Bosse MJ, Seymour RB, Holden MB, Gitajn IL, Goldhaber SZ, Eastman AL, Jurkovich GJ, Vallier HA, Gary JL, Kleweno CP, Cuschieri J, Marvel D, Castillo RC; METRC. O'Toole RV, et al. BMJ Open. 2021 Mar 24;11(3):e041845. doi: 10.1136/bmjopen-2020-041845. BMJ Open. 2021. PMID: 33762229 Free PMC article.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance.
Durno C, Ercan AB, Bianchi V, Edwards M, Aronson M, Galati M, Atenafu EG, Abebe-Campino G, Al-Battashi A, Alharbi M, Azad VF, Baris HN, Basel D, Bedgood R, Bendel A, Ben-Shachar S, Blumenthal DT, Blundell M, Bornhorst M, Bronsema A, Cairney E, Rhode S, Caspi S, Chamdin A, Chiaravalli S, Constantini S, Crooks B, Das A, Dvir R, Farah R, Foulkes WD, Frenkel Z, Gallinger B, Gardner S, Gass D, Ghalibafian M, Gilpin C, Goldberg Y, Goudie C, Hamid SA, Hampel H, Hansford JR, Harlos C, Hijiya N, Hsu S, Kamihara J, Kebudi R, Knipstein J, Koschmann C, Kratz C, Larouche V, Lassaletta A, Lindhorst S, Ling SC, Link MP, Loret De Mola R, Luiten R, Lurye M, Maciaszek JL, MagimairajanIssai V, Maher OM, Massimino M, McGee RB, Mushtaq N, Mason G, Newmark M, Nicholas G, Nichols KE, Nicolaides T, Opocher E, Osborn M, Oshrine B, Pearlman R, Pettee D, Rapp J, Rashid M, Reddy A, Reichman L, Remke M, Robbins G, Roy S, Sabel M, Samuel D, Scheers I, Schneider KW, Sen S, Stearns D, Sumerauer D, Swallow C, Taylor L, Thomas G, Toledano H, Tomboc P, Van Damme A, Winer I, Yalon M, Yen LY, Zapotocky M, Zelcer S, Ziegler DS, Zimmermann S, Hawkins C, Malkin D, Bouffet E, Villani A, Tabori U. Durno C, et al. J Clin Oncol. 2021 Sep 1;39(25):2779-2790. doi: 10.1200/JCO.20.02636. Epub 2021 May 4. J Clin Oncol. 2021. PMID: 33945292 Free PMC article.

By contrast, only 16% of hematologic malignancies were detected asymptomatically (P < .001). Eighty-nine patients were followed prospectively and used for survival analysis. Five-year overall survival (OS) was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) whe

By contrast, only 16% of hematologic malignancies were detected asymptomatically (P < .001). Eighty-nine patients were followed pr

Observation of the B_{s}^{0}→X(3872)ϕ Decay.
Sirunyan AM, Tumasyan A, Adam W, Ambrogi F, Bergauer T, Dragicevic M, Erö J, Escalante Del Valle A, Frühwirth R, Jeitler M, Krammer N, Lechner L, Liko D, Madlener T, Mikulec I, Pitters FM, Rad N, Schieck J, Schöfbeck R, Spanring M, Templ S, Waltenberger W, Wulz CE, Zarucki M, Chekhovsky V, Litomin A, Makarenko V, Suarez Gonzalez J, Darwish MR, De Wolf EA, Di Croce D, Janssen X, Kello T, Lelek A, Pieters M, Rejeb Sfar H, Van Haevermaet H, Van Mechelen P, Van Putte S, Van Remortel N, Blekman F, Bols ES, Chhibra SS, D'Hondt J, De Clercq J, Lontkovskyi D, Lowette S, Marchesini I, Moortgat S, Morton A, Python Q, Tavernier S, Van Doninck W, Van Mulders P, Beghin D, Bilin B, Clerbaux B, De Lentdecker G, Delannoy H, Dorney B, Favart L, Grebenyuk A, Kalsi AK, Makarenko I, Moureaux L, Pétré L, Popov A, Postiau N, Starling E, Thomas L, Vander Velde C, Vanlaer P, Vannerom D, Wezenbeek L, Cornelis T, Dobur D, Gruchala M, Khvastunov I, Niedziela M, Roskas C, Skovpen K, Tytgat M, Verbeke W, Vermassen B, Vit M, Bruno G, Bury F, Caputo C, David P, Delaere C, Delcourt M, Donertas IS, Giammanco A, Lemaitre V, Mondal K, Prisciandaro J, Taliercio A, Teklishyn M, Vischia P, Wuyckens S, Zobec J, Alves G… See abstract for full author list ➔ Sirunyan AM, et al. Phys Rev Lett. 2020 Oct 9;125(15):152001. doi: 10.1103/PhysRevLett.125.152001. Phys Rev Lett. 2020. PMID: 33095627
Risk-stratified thromboprophylaxis effects of aspirin versus low-molecular-weight heparin in orthopedic trauma patients: A secondary analysis of the PREVENT CLOT trial.
O'Hara NN, O'Toole RV, Frey KP, Castillo RC, Cuschieri J, Haut ER, Slobogean GP, Firoozabadi R, Christmas AB, Obremskey WT, Carlini AR, Gaski GE, Kutcher ME, Marvel D, Stein DM; Major Extremity Trauma Research Consortium (METRC). O'Hara NN, et al. J Trauma Acute Care Surg. 2024 Apr 1;96(4):573-582. doi: 10.1097/TA.0000000000004226. Epub 2023 Dec 8. J Trauma Acute Care Surg. 2024. PMID: 38079260
Among high risk patients, thromboembolic events did not differ statistically between aspirin and LMWH (win ratio, 0.94; 95% confidence interval [CI], 0.82-1.08, p = 0.42). This result was consistent in the low (win ratio, 1.15; 95% CI, 0.90-1.47, p = 0.27), low-medi …
Among high risk patients, thromboembolic events did not differ statistically between aspirin and LMWH (win ratio, 0.94; 95% confidence inter …
Observation of tt[over ¯]H Production.
Sirunyan AM, Tumasyan A, Adam W, Ambrogi F, Asilar E, Bergauer T, Brandstetter J, Dragicevic M, Erö J, Escalante Del Valle A, Flechl M, Frühwirth R, Ghete VM, Hrubec J, Jeitler M, Krammer N, Krätschmer I, Liko D, Madlener T, Mikulec I, Rad N, Rohringer H, Schieck J, Schöfbeck R, Spanring M, Spitzbart D, Taurok A, Waltenberger W, Wittmann J, Wulz CE, Zarucki M, Chekhovsky V, Mossolov V, Suarez Gonzalez J, De Wolf EA, Di Croce D, Janssen X, Lauwers J, Pieters M, Van De Klundert M, Van Haevermaet H, Van Mechelen P, Van Remortel N, Abu Zeid S, Blekman F, D'Hondt J, De Bruyn I, De Clercq J, Deroover K, Flouris G, Lontkovskyi D, Lowette S, Marchesini I, Moortgat S, Moreels L, Python Q, Skovpen K, Tavernier S, Van Doninck W, Van Mulders P, Van Parijs I, Beghin D, Bilin B, Brun H, Clerbaux B, De Lentdecker G, Delannoy H, Dorney B, Fasanella G, Favart L, Goldouzian R, Grebenyuk A, Kalsi AK, Lenzi T, Luetic J, Postiau N, Starling E, Thomas L, Vander Velde C, Vanlaer P, Vannerom D, Wang Q, Cornelis T, Dobur D, Fagot A, Gul M, Khvastunov I, Poyraz D, Roskas C, Trocino D, Tytgat M, Verbeke W, Vermassen B, Vit M, Zaganidis N, Bakhshiansohi H, Bondu O, Brochet S, Bruno G, Caputo C, David P, Dela… See abstract for full author list ➔ Sirunyan AM, et al. Phys Rev Lett. 2018 Jun 8;120(23):231801. doi: 10.1103/PhysRevLett.120.231801. Phys Rev Lett. 2018. PMID: 29932697 Free article.
135 results